Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.39 |
| ▸ | PPARA | Q07869 | 6/20 | 0.39 |
| ▸ | PPARD | Q03181 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | HTR6 | P50406 | 4/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14124687 | 0.90 | PPARG (0.41) | PPARGPPARAPPARDALDH1A1L3MBTL1 | |
| SCHEMBL12096728 | 0.84 | PPARG (0.53) | PPARGPPARAPPARDALDH1A1L3MBTL1 | |
| SCHEMBL14053616 | 0.82 | TP53 (0.42) | PPARGPPARAPPARDALDH1A1L3MBTL1 | |
| SCHEMBL14124693 | 0.82 | MRGPRX4 (0.41) | PPARGPPARAPPARDALDH1A1KDM4E | |
| SCHEMBL15519194 | 0.82 | RORC (0.46) | PPARGPPARAPPARDALDH1A1L3MBTL1 | |
| SCHEMBL14053938 | 0.81 | PPARG (0.38) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL14058394 | 0.80 | PPARG (0.38) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL14054058 | 0.80 | PPARG (0.38) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL14053566 | 0.80 | PPARG (0.39) | PPARGPPARAPPARDRORC | |
| SCHEMBL14054024 | 0.79 | PPARG (0.40) | PPARGPPARAPPARDRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521727-B1 | NEW BENZOIC PYRROLOPYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PARKINSON'S DISEASE | INVENTIVA (FR) | 2014-03-19 | — | — | EP | disclosed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | NCOR1, NCOR2, NR0B1 | PPARG 133/4885PPARA 151/4885PPARD 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.